These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 21894646)
1. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Dawson J; Walters M Br J Clin Pharmacol; 2006 Dec; 62(6):633-44. PubMed ID: 21894646 [TBL] [Abstract][Full Text] [Related]
2. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Dawson J; Quinn T; Walters M Curr Med Chem; 2007; 14(17):1879-86. PubMed ID: 17627523 [TBL] [Abstract][Full Text] [Related]
3. Uric acid lowering therapy in cardiovascular diseases. Volterrani M; Iellamo F; Sposato B; Romeo F Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814 [TBL] [Abstract][Full Text] [Related]
4. Uric acid: role in cardiovascular disease and effects of losartan. Alderman M; Aiyer KJ Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846 [TBL] [Abstract][Full Text] [Related]
5. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition? Schuchardt M; Herrmann J; Tolle M; van der Giet M Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972 [TBL] [Abstract][Full Text] [Related]
6. Hyperuricaemia and vascular risk: the debate continues. Landolfo M; Borghi C Curr Opin Cardiol; 2019 Jul; 34(4):399-405. PubMed ID: 30925517 [TBL] [Abstract][Full Text] [Related]
7. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Bomalaski JS; Clark MA Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605 [TBL] [Abstract][Full Text] [Related]
8. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Gavin AR; Struthers AD Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064 [TBL] [Abstract][Full Text] [Related]
9. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K; Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093 [TBL] [Abstract][Full Text] [Related]
10. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Maruhashi T; Hisatome I; Kihara Y; Higashi Y Atherosclerosis; 2018 Nov; 278():226-231. PubMed ID: 30326405 [TBL] [Abstract][Full Text] [Related]
11. Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. Zhang Y; Li Y; Li C; Zhao Y; Xu L; Ma S; Lin F; Xie Y; An J; Wang S Phytomedicine; 2023 Sep; 118():154957. PubMed ID: 37478683 [TBL] [Abstract][Full Text] [Related]